Dose-Escalation Study of CLR 131 in Relapsed or Refractory Multiple Myeloma
Early results from a dose-escalating phase I trial investigating CLR 131 in heavily treated patients with multiple myeloma revealed that those who received the lowest dose of survived for a median of 26.2 months. CLR 131, a phospholipid drug conjugate that has received Orphan Drug designation by the U.S. Food and Drug Administration for the treatment of multiple myeloma, delivers a radioactive, toxic compound directly to cancer cells by targeting specific lipid molecules in their membrane.
Patients in the study were assigned to one of three cohorts. In the first cohort, the 26.2-month median overall survival was observed following a single 30-minute infusion of 12.5 mCi/m2 in patients who had an average of nearly 6 prior lines of therapy. The second cohort, which received a single dose of 18.75 mCi/m2, had a median overall survival of 15.4 months to date; the third cohort, which received a single dose of 25 mCi/m2, had a median overall survival of 10 months to date.
The early results of this ongoing trial (NCT02278315) were reported by Alice Melão in Myeloma Research News. CLR 131 also is being tested in combination with dexamethasone in a phase II trial (NCT02952508) in patients with relapsed or refractory B-cell malignancies.